Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: Evidence from a rural community in Tanzania

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Kabanywanyi, Abdunoor M ^a   Lengeler, Christian ^b   Kasim, Prudensiana ^a   King'Eng'Ena, Said ^a   Schlienger, Raymond ^c   Mulure, Nathan ^d   Genton, Blaise ^a,b  

^a IFAKARA HEALTH INSTITUTE   (Tanzania)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Novartis Pharma (EACA)   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BLISTER PACK; CHILD; CHILD CARE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG USE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MICROSCOPY; PATIENT CODING; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; SCHOOL CHILD; TANZANIA; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PATIENT ATTITUDE; PROSPECTIVE STUDY; RURAL POPULATION; STATISTICS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MEDICATION ADHERENCE; PATIENT ACCEPTANCE OF HEALTH CARE; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; QUESTIONNAIRES; RURAL POPULATION; TANZANIA; TREATMENT OUTCOME;

EID: 77949302543     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-48     Document Type: Article

References (32)

1. World Health Organization, World Malaria Report WHO Press, World Health Organization, Geneva, Switzerland 2008 ISBN 978 92 4 156369 7
2. The burden of malaria mortality among African children in the year 2000. AK Rowe SY Rowe RW Snow EL Korenromp JR Schellenberg C Stein BL Nahlen J Bryce RE Black RW Steketee, Int J Epidemiol 2006 35 691 704 10.1093/ije/dyl027 16507643
3. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. JG Breman MS Alilio A Mills, Am J Trop Med Hyg 71 Suppl 2 1S 15S
4. Estimates of the burden of malaria morbidity in African in children under the age of 5 years. A Roca-Feltrer I Carneiro JR Armstrong Schellenberg, Trop Med Int Health 2008 13 771 783 18363586
5. The economic and social burden of malaria. J Sachs P Malaney, Nature 2002 415 680 685 10.1038/415680a 11832956
6. The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis. P Ayieko AO Akumu UK Griffiths M English, Cost Effec Resour Alloc 2009 7 3 10.1186/1478-7547-7-3
7. [Limits of the efficacy of chloroquine and sulfadoxine-pyrimethamine in Northern Abidjan (Cote d'Ivoire): Combined in vivo and in vitro studies](in French). J Djaman S Abouanou L Basco M Koné Sante 2004 14 205 209 15745869
8. Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. K Mugittu B Genton H Mshinda HP Beck, Malar J 2006 5 126 10.1186/1475-2875-5-126 17177997
9. Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies. K Mugittu S Abdulla N Falk H Masanja I Felger H Mshinda HP Beck B Genton, Malar J 2005 4 55 10.1186/1475-2875-4-55 16297234
10. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. K Mugittu M Ndejembi A Malisa M Lemnge Z Premji A Mwita W Nkya J Kataraihya S Abdulla HP Beck H Mshinda, Am J Trop Med Hyg 2004 71 696 702 15642957
11. Guidelines for the treatment of malaria. World Health Organization, 2006 http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf Accessed 18 August, 2009
12. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. G Kokwaro L Mwai A Nzila, Expert Opin Pharmacother 2007 8 75 94 10.1517/14656566.8.1.75 17163809
13. Antimalarial pharmacokinetics and treatment regimens. NJ White, Br J Clin Pharmacol 1992 34 1 10 1633062
14. 1) tablets (six-dose regimen) in African infants and children with acute, uncomplicated malaria. C Falade M Makanga Z Premji CE Ortmann M Stockmeyer PI de Palacios, Trans R Soc Trop Med Hyg 2005 99 459 467 10.1016/j.trstmh.2004.09.013 15837358
15. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. B Faye JL Ndiaye D Ndiaye Y Dieng O Faye O Gaye, Malar J 2007 6 80 10.1186/1475-2875-6-80 17570848
16. A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. CI Fanello C Karema W van Doren C Van Overmeir D Ngamije U D'Alessandro, Trans R Soc Trop Med Hy 2007 101 344 350 10.1016/j.trstmh.2006.06.010
17. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. AA Omari C Gamble P Garner, Cochrane Database Syst Rev 2005 4 D005564 16235412
18. Artemisinin-based combination therapy for treating uncomplicated malaria. D Sinclair B Zani S Donegan P Olliaro P Garner, Cochrane Database Syst Rev 2009 3 D007483 19588433
19. 1 (artemether/lumefantrine) Basic Prescribing Information. Novartis Pharma AG, Basel, Switzerland. Last updated September 2007 http://www.pharma.us.novartis.com/product/pi/pdf/coartem.pdf
20. Efficacy and safety of the six-dose regimen of arthemeter-lumefrantrine in pediatrics with uncomplicated plasmodium falciparum malaria: a pooled analysis of individual patient data. M Makanga Z Premji C Falade J Karbwang EA Mueller K Andriano P Hunt PI De Palacios, Am J Trop Med Hyg 2006 74 991 998 16760509
21. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. M van Vugt S Looareesuwan P Wilairatana R McGready L Villegas I Gathmann R Mull A Brockman NJ White F Nosten, Trans R Soc Trop Med Hyg 2000 94 545 548 10.1016/S0035-9203(00)90082-8 11132386
22. A clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. G Lefévre S Looareesuwan S Treeprasertsuk S Krudsood U Silachamroon I Gathmann R Mull R Bakshi, Am J Trop Med Hyg 2001 64 247 256 11463111
23. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomized trial. P Piola C Fogg F Bajunirwe S Biraro F Grandesso E Ruzagira J Babigumira I Kigozi J Kiguli J Kyomuhendo L Ferradini W Taylor F Checchi JP Guthmann, Lancet 2005 365 1467 1473 10.1016/S0140-6736(05)66416-1 15850630
24. Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites. IO Ajayi EN Browne B Garshong F Bateganya B Yusuf P Agyei-Baffour L Doamekpor A Balyeku K Munguti S Cousens F Pagnoni, Malar J 2008 7 6 10.1186/1475-2875-7-6 18182114
25. A qualitative study of the feasibility and community perception on the effectiveness of artemether-lumefantrine use in the context of home management of malaria in south-west Nigeria. IO Ajayi CO Falade BO Olley B Yusuf S Gbotosho T Iyiola O Olaniyan C Happi K Munguti F Pagnoni, BMC Health Serv Res 2008 8 119 10.1186/1472-6963-8-119 18513447
26. Feasibility and acceptability of the use of artemether-lumefantrine in the home management of uncomplicated malaria in children 6-59 months old in Ghana. AM Chinbuah JO Gyapong F Pagnoni EK Wellington M Gyapong, Trop Med Int Health 2006 11 1003 1016 10.1111/j.1365-3156.2006.01654.x 16827701
27. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. MM Rahman AM Donorp NP Day N Lindegardh M Imwong MA Faiz AM Bangali AT Kamal J Karim J Kaewkungwal P Singhasivanon, Trans R Soc Trop Med Hyg 2008 102 861 867 10.1016/j.trstmh.2008.05.022 18606428
28. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. C Fogg F Bajunirwe P Piola S Biraro F Checchi J Kiguli P Namiro J Musabe A Kyomugisha J-P Gushtmann, Am J Trop Med 2004 71 525 530
29. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. DJ Bell D Wootton M Mukaka J Montgomery N Kayange P Chimpeni DA Hughes ME Molyneux SA Ward PA Winstanley DG Lalloo, Malar J 2009 26 204 10.1186/1475-2875-8-204
30. Medicine labels incorporating pictograms: do they influence understanding and adherence? R Dowse M Ehlers, Patient Educ Couns 2005 58 63 70 10.1016/j.pec.2004.06.012 15950838
31. Exposure to lumefantrine in infants and children receiving artemether-lumefantrine for uncomplicated malaria: impact of African diet components. S Borrmann WM Sallas AC Marrast SE Kern, American Society of Tropical Medicine and Hygiene Annual Meeting, 7-11 December 2008, New Orleans, USA
32. The concordance of self-report with other measures of medication adherence: a summary of the literature. MC Garber DP Nau SR Erickson JE Aikens JB Lawrence, Med Care 2004 42 649 652 10.1097/01.mlr.0000129496.05898.02 15213489